19results
-
Press
SK Inc. announces First-Ever ‘Value-Up’ Plan Among Korean Holding Companies…
SK Inc. announced plans to enhance the stability and scale of shareholder returns, targeting corporate value growth through portfolio rebalancing, strengthening financial resilience, and improving operational efficiency.
-
Press
SK pharmteco to showcase its extensive APIs and CGT capabilities in CPHI 2023
- With a dedicated booth in the main exhibition hall, SK pharmteco solidifies its global position as the most trusted CDMO partner in the pharmaceutical industry - Appoints Chief Commercial Officer Andrew Fenny to strengthen its global marketing capabilities - Shortlisted as a finalist for the 2023 CPHI Pharma Awards in the Accelerating Innovation category
-
Press
SK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in CBM
-CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and continues SK pharmteco’s strategy to deliver end-to-end, multi-modality support for clients -SK pharmteco previously invested $350 million in CBM in 2022
-
Press
SK Inc.’s board of directors declares an interim dividend of KRW 1,500 per share
- The first interim dividend payout after Articles of Incorporation were amended to enable investors to invest after checking dividend amount - Shareholders of record as of August 10, 2023 will receive dividend payout
-
Press
SK pharmteco doubles viral vector production capacity in Europe
Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapy, completes its second bioproduction facility and doubles its manufacturing footprint to 10,000m2, one of the largest in Europe - Operation of the second facility to kick start in 2024